Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor

Stanway, Susannah J and Purohit, Atul and Woo, L W Lawrence and Sufi, Saulat and Vigushin, David and Ward, Rebecca and Wilson, Richard H and Stanczyk, Frank Z and Dobbs, Nicola and Kulinskaya, Elena and Elliott, Moira and Potter, Barry V L and Reed, Michael J and Coombes, R Charles (2006) Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. Clinical Cancer Research, 12 (5). pp. 1585-92. ISSN 1078-0432 (https://doi.org/10.1158/1078-0432.CCR-05-1996)

Full text not available in this repository.Request a copy

Abstract

Inhibition of steroid sulfatase (STS), the enzyme responsible for the hydrolysis of steroid sulfates, represents a potential novel treatment for postmenopausal women with hormone-dependent breast cancer. Estrone and DHEA are formed by this sulfatase pathway and can be converted to steroids (estradiol and androstenediol, respectively), which have potent estrogenic properties.

CORE (COnnecting REpositories)